Verastem, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 87.37 million compared to USD 73.81 million a year ago. Basic loss per share from continuing operations was USD 3.96 compared to USD 4.57 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.9 USD | +5.21% | +16.20% | +33.91% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 18 | Verastem Oncology Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.91% | 276M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- VSTM Stock
- News Verastem, Inc.
- Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023